Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pulmonary Drugs Market Grown from 2024 to 2025?

The market size for pulmonary drugs has seen considerable growth in the recent past. It is projected to escalate from $54.28 billion in 2024 to $57.53 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.0%. The growth during the historical period is a result of the increased prevalence of respiratory disorders, a rise in the rates of smoking, a swelling geriatric population, expanding access to healthcare, and a significant increase in pollution levels.

What Growth Rate Is Anticipated for the Pulmonary Drugs Market in the Coming Years?

In the upcoming years, the market size for pulmonary drugs is projected to witness robust growth, increasing to $71.91 billion by 2029 with a compound annual growth rate (CAGR) of 5.7%. This expansion during the forecast period is due to numerous factors such as the improvement of healthcare infrastructure, an increase in cardiovascular diseases, the growth of homecare treatments, heightened understanding of pulmonary diseases, and a surge in asthma cases. Key trends for the forecast period encompass technological innovation, the application of artificial intelligence in drug discovery, the usage of smart inhalers, the introduction of nanotechnology in drug formulation, and progress in gene therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Who Are the Leading Companies in the Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

What Are the Key Drivers of the Pulmonary Drugs Market?

The escalating occurrence of respiratory afflictions is anticipated to stimulate the expansion of the pulmonary drugs market in the future. Respiratory ailments involve medical issues that impact the lungs and airways, hindering regular breathing and the exchange of oxygen. The amplification of respiratory diseases is due to the increasing rate of smoking, which results in lung damage and chronic illnesses. Pulmonary medications are essential in managing respiratory ailments by enhancing lung performance, diminishing inflammation, and easing airway blockage for improved respiration. For example, the Bureau of Labor Statistics, a governmental agency in the US, reported in November 2023 that the disease rate amongst private sector employers in 2022 jumped to 45.2 cases per 10,000 FTE workers from 37.7 cases in 2021. This surge is primarily credited to the higher prevalence of respiratory diseases, which leaped from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Consequently, the escalating respiratory ailments are fueling the expansion of the pulmonary drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

What Are the Key Market Segments in the Pulmonary Drugs Industry?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Are the Latest Trends in the Pulmonary Drugs Market?

Pulmonary drugs market giants are concentrating their efforts on devising innovative treatments, such as single-inhaler triple therapy (SITT), with the goal of amplifying treatment effectiveness, endorsing patient compliance, and streamlining medication regimens for superior disease management. SITT is a multifaceted treatment method, combining three different drugs into one inhaler to support the management of chronic respiratory ailments like chronic obstructive pulmonary disease (COPD). For example, in April 2022, Trelegy Ellipta was introduced by GlaxoSmithKline Pharmaceuticals Limited, an Indian pharmaceutical firm, marking a first for India in single-inhaler triple therapy (SITT) for patients with COPD. The introduction of this therapy, which fuses fluticasone furoate, umeclidinium, and vilanterol, aims to augment lung function and diminish symptom flare-ups. The advanced Ellipta inhaler guarantees precise dosing and promotes patient consistency in comparison to therapies involving multiple inhalers. This new development is geared towards simplifying treatment procedures and enhancing patient health outcomes, marking a significant step considering India is home to more than 100 million COPD patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

What Are the Key Regional Markets in the Pulmonary Drugs Industry?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23489

This Report Delivers Insight On:

1. How big is the pulmonary drugs market, and how is it changing globally?

2. Who are the major companies in the pulmonary drugs market, and how are they performing?

3. What are the key opportunities and risks in the pulmonary drugs market right now?

4. Which products or customer segments are growing the most in the pulmonary drugs market?

5. What factors are helping or slowing down the growth of the pulmonary drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model